Ghrelin and acyl ghrelin levels are associated with inflammatory and nutritional markers and with cardiac and vascular dysfunction parameters in hemodialysis patients
- 33 Downloads
Exogenous ghrelin is associated with cardiovascular protection in experimental and human studies. Nevertheless ESRD patients have increased ghrelin levels and severe cardiovascular comorbidities. This study aims to elucidate the metabolic factors influencing endogenous ghrelin/acyl ghrelin levels and to analyze the relation between endogenous ghrelin/acyl ghrelin levels and cardiac and vascular function markers in hemodialysis patients.
The cross-sectional study was conducted in hemodialysis patients (n = 88); 50 of them were men, mean age 61.1 ± 13.5 years, 17% had diabetes. We assessed nutritional and inflammatory status and analyzed the determinants of ghrelin/acyl ghrelin and their relation with cardiac and vascular function.
Ghrelin is correlated with IL-1β (r = 0.88, p < 0.0001), triglycerides, total cholesterol (TC), and Kt/V. IL-1β is the strongest predictor of ghrelin levels (p < 0.0001). Acyl ghrelin is correlated with TC (r = 0.36, p = 0.001), LDL-cholesterol, serum bicarbonate, body mass index. TC is the strongest predictor for acyl ghrelin levels (p = 0.038). Patients with high ghrelin levels had significantly decreased nitroglycerin-mediated dilation (p = 0.05) and higher IL-1β levels (p < 0.001); increased NT-proBNP is associated with lower levels of acyl ghrelin (r = − 0.33, p = 0.02) in male patients.
The inflammatory marker IL-1β is in our study the strongest predictor of ghrelin levels while the nutritional marker-total cholesterol is the strongest predictor for acyl ghrelin levels in HD patients. High endogenous ghrelin level is associated with high IL-1β and with vascular smooth muscle cell dysfunction. Low acyl ghrelin level is associated with high NT-proBNP (a cardiac dysfunction marker) in male HD patients. There is a direct correlation between endogenous ghrelin level and inflammatory markers, which is not related with cardiovascular protection.
KeywordsGhrelin IL-1β Nutritional status Inflammation Cardiovascular disease Chronic kidney failure
Compliance with ethical standards
Conflict of interest
The authors report no conflict of interest.
- 15.Enomoto M, Nagaya N, Uematsu M, Okumura H, Nakagawa E, Ono F, Hosoda H, Oya H, Kojima M, Kanmatsuse K, Kangawa K (2003) Cardiovascular and hormonal effects of subcutaneous administration of ghrelin, a novel growth hormone-releasing peptide. in healthy humans Clin Sci (Lond) 105:431–435CrossRefGoogle Scholar
- 18.Onofriescu M, Mardare NG, Segall L, Voroneanu L, Cuşai C, Hogaş S, Ardeleanu S, Nistor I, Prisadă OV, Sascău R, Covic A (2012) Randomized trial of bioelectrical impedance analysis versus clinical criteria for guiding ultrafiltration in hemodialysis patients: effects on blood pressure, hydration status, and arterial stiffness. Int Urol Nephrol 44:583–591CrossRefPubMedGoogle Scholar
- 31.Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, Franch H, Guarnieri G, Ikizler TA, Kaysen G, Lindholm B, Massy Z, Mitch W, Pineda E, Stenvinkel P, Treviño-Becerra A, Wanner C (2008) A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 73:391–398CrossRefPubMedGoogle Scholar
- 37.Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members (2014) KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 85:1303–1309CrossRefPubMedGoogle Scholar
- 38.Khatib MN, Shankar A, Kirubakaran R, Agho K, Simkhada P, Gaidhane S, Saxena D, Gode BU, Gaidhane D, Zahiruddin ASQ (2015) Effect of ghrelin on mortality and cardiovascular outcomes in experimental rat and mice models of heart failure: a systematic review and meta-analysis. PLoS ONE 10(5):e0126697. https://doi.org/10.1371/journal.pone.0126697 CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Schwermer K, Hoppe K, Radziszewska D, Kłysz P, Sawatiuk P, Nealis J, Kałużna M, Kaczmarek J, Baum E, Lindholm B, Pawlaczyk K, Oko A (2015) Nterminal proB-type natriuretic peptide as a marker of hypervolemia and predictor of increased mortality in patients on hemodialysis. Pol Arch Med Wewn 125:560–569PubMedGoogle Scholar
- 48.Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, Kajikawa M, Matsumoto T, Hidaka T, Kihara Y, Chayama K, Noma K, Nakashima A, Goto C, Higashi Y (2013) Nitroglycerine-induced vasodilation for assessment of vascular function: a comparison with flow-mediated vasodilation. Arterioscler Thromb Vasc Biol 33:1401–1408CrossRefPubMedGoogle Scholar
- 50.Akamatsu D, Sato A, Goto H, Watanabe T, Hashimoto M, Shimizu T, Sugawara H, Sato H, Nakano Y, Miura T, Zukeran T, Serizawa F, Hamada Y, Tsuchida K, Tsuji I, Satomi S (2010) Nitroglycerin-mediated vasodilatation of the brachial artery may predict long-term cardiovascular events irrespective of the presence of atherosclerotic disease. J Atheroscler Thromb 17:1266–1274CrossRefPubMedGoogle Scholar
- 52.dell’Oglio MP, Simone S, Ciccone M, Corciulo R, Gesualdo M, Zito A, Cortese F, Castellano G, Gigante M, Gesualdo L, Grandaliano G, Pertosa GB (2017) Neutrophil-dependent pentraxin-3 and reactive oxygen species production modulate endothelial dysfunction in haemodialysis patients. Nephrol Dial Transplant 32:1540–1549PubMedGoogle Scholar